Paxlovid, Drug Exposure

Variable Name

rx_paxlovid

Created

2022-10-10

Last Modified

Thumbnail Image

Files

2 Downloads↓
rx_2022_10_Paxlovid_V1.csv (6.96 KB)
↓
FIND_PAXLOVID_FUNCTION.R (4.69 KB)
↓

Tags

Level of Review

Data Model

Abstract

The concept set was intended to identify all patients with a drug_exposure record indicating a Paxlovid exposure (nirmatrelvir/ritonavir).

Affiliation(s)

Children's Hospital of Philadelphia

Funder(s)

Provenance

Initially developed for a "Researching COVID to Enhance Recovery (RECOVER) Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study" Y1, Q3 query. The concepts were later reviewed and refined for a brief report on pediatric nirmatrelvir and ritonavir prescribing patterns, "Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic" (Bose-Brill et. al., 2022).

Description

This concept set was used to identify pediatric patients under 18 who were prescribed Paxlovid.

The concept set was developed by identifying RxNorm codes at the SCDF/SCDG level and descendants indicating Paxlovid, then string searching for the terms ‘paxlovid’, ‘ritonavir’, and ‘nirmatrelvir’ in ‘concept_name’. Codes were identified in the ‘code_type’ column as ‘Paxlovid’ (indicating nirmatrelvir/ritonavir), ‘nirmatrelvir’ (indicating nirmatrelvir alone) and ‘ritonavir’ (indicating ritonavir alone).

Please note, this concept set should not be used without appropriate accompanying logic to identify Paxlovid; the concept set contains individual ingredients that comprise the combination. Ritonavir and nirmatrelvir exposure must occur together on the same date to indicate a combination drug prescription. The attached file, FIND_PAXLOVID_FUNCITON.R, provides logic showing how the concept set can be used.

Development Code

https://atlassian.chop.edu/bitbucket/projects/COV/repos/paxlovid_brief/browse

Vocabulary

Medication Classification Level



Clinical Subjects Headings

Data Source

Related Phenotype

Related Person

Related Study

Thumbnail Image
The Researching COVID to Enhance Recovery (RECOVER) Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study
Children's Hospital of Philadelphia; Janssen (United States)
Study to understand, prevent, and treat post-acute sequelae of SARS-CoV-2 (PASC), including Long COVID.
Thumbnail Image
Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic
Stanford Medicine
Study to identify demographic and clinical factors prompting clinician prescribing of nirmatrelvir/ritonavir to pediatric patients for management of coronavirus disease 2019 (COVID-19) infection.

Related Concept Set

Related Code

Related Publications

Bose-Brill S, Hirabayashi K, Pajor NM, Rao S, Mejias A, Jhaveri R, Forrest CB, et al. 2022. “Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic”. medRxiv [Preprint]. 2022 Dec 26:2022.12.23.22283868.
DOI: 10.1101/2022.12.23.22283868
Update in: Hosp Pediatr. 2024 Aug 1;14(8):e341-e348.
DOI: 10.1542/hpeds.2023-007132

Creative Commons license

a CC-BY Attribution 4.0 License.
Except where otherwised noted, this item's license is described as a CC-BY Attribution 4.0 License.

Cite this Concept Set

Hirabayashi, K.. (2022, October). Paxlovid, Drug Exposure. [Concept Set]. PEDSpace Knowledge Bank. https://doi.org/10.24373/pdsp-320